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Abstract 1 
Background 2 
In Sub-Saharan Africa, both under-treatment and over-treatment of malaria are common since 3 
illnesses are often diagnosed and treated on the basis of symptoms. We investigate whether 4 
malaria treatment rates among febrile individuals correspond to observed patterns of malaria 5 
infection by age and by local prevalence.  6 
Methods and Findings 7 
We use data on treatment of febrile illnesses from a household survey that was conducted 8 
between March and May 2012 in 92 villages in six districts in Eastern Uganda.  All household 9 
members were also tested for malaria using a rapid diagnostic test. We show that both the age of 10 
the febrile individual and the village prevalence rate are strongly associated with the odds that a 11 
febrile patient was infected with malaria, but not with the odds of ACT treatment. Compared to 12 
individuals who were aged 15 or above, febrile individuals aged 5-14 had 3.21 times the odds of 13 
testing positive for malaria 95% CI: [2.36  4.37], P<0·001), and febrile individuals who were 14 
under age 5 had 2.66 times the odds of testing positive for malaria (95% CI: [1.99 3.56], 15 
P<0·001).  However, ACT treatment rates for febrile illnesses were not significantly higher for 16 
either children ages 5-14 (Unadjusted OR: 1.19, 95% CI: [0.88 1.62], P=0.255) or children under 17 
the age of 5 (Unadjusted OR: 1.24, 95% CI: [0.92 1.68], P=0·154). A one standard deviation 18 
increase in the village malaria prevalence rate was associated with a 2.03 times higher odds that 19 
a febrile individual under the age of five tested positive for malaria (95% CI: [1.63 2.54], 20 
p<0·001), but was not significantly associated with the odds of ACT treatment (Un-adjusted OR: 21 
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0.83, 95% CI: [0.66 1.05], P=0·113). We present some evidence that this discrepancy may be 22 
because caregivers do not suspect a higher likelihood of malaria infection, conditional on fever, 23 
in young children or in high-prevalence villages.  24 
Conclusion 25 
Our findings suggest that households have significant mis-perceptions about malaria likelihood 26 
that may contribute to the under-treatment of malaria. Policies are needed to encourage 27 
caregivers to seek immediate diagnostic testing and treatment for febrile illnesses, particularly 28 
among young children. 29 
 30 
 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
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Introduction 41 
Malaria continues to pose a large morbidity and mortality burden with an estimated 214 42 
million cases in 2015 and nearly 440,000 deaths [1]. A majority of these deaths occur in Sub-43 
Saharan Africa, primarily among young children, and could likely be avoided with prompt 44 
treatment of the illness with artemisinin-based combination therapies (ACTs), the first-line 45 
treatment for uncomplicated malaria [1,2].  46 
In most countries, ACTs are freely available at public sector health facilities, and there 47 
are efforts to make them available at subsidized prices in the private sector, where many people 48 
first seek care for suspected malaria [3]. However, it is estimated that only 12-22% of malaria 49 
cases in children under age five were treated with ACTs in 2014. This low level of coverage with 50 
appropriate treatment is partly due to the fact that nearly 45% of children with fever (the primary 51 
symptom of malaria) either did not get any care outside the home or sought care in the informal 52 
private sector, where they are less likely to get ACTs than if they sought public sector treatment 53 
[1]. Even when patients do use public health facilities, they do not always receive ACTs [1,4]. 54 
At the same time, many individuals who do not have malaria are treated with ACTs. 55 
Malaria is often diagnosed and treated on the basis of symptoms such as fever, chills, headache, 56 
fatigue, and nausea, which overlap with several other common bacterial and viral illnesses such 57 
as pneumonia or the flu [5,6]. The World Health Organization (WHO) now recommends 58 
universal diagnostic testing for malaria, and diagnostic confirmation of malaria cases in the 59 
African public health sector has increased from 36% to over 60% between 2005 and 2014 [1]. 60 
However ACT treatment for non-malarial illnesses is still common, partly because many 61 
individuals seek care in the private sector where diagnostic testing is very limited, but also 62 
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because health workers, caregivers and sick individuals often treat illnesses with ACTs even if 63 
the individual tests negative for malaria [7–9].  64 
Although it is difficult to identify malaria cases on the basis of symptoms alone, the age 65 
of the individual and the local malaria prevalence are strong predictors of malaria infection status 66 
[10,11]. For example, a review of studies across sub-Saharan Africa finds that the median 67 
proportion of fevers attributable to malaria was 36% among children under five years and 26% 68 
for those aged five and above[12]. Another study estimates that, across Africa, only 3.3% of 69 
febrile children presenting at clinics in low malaria prevalence areas were infected with malaria, 70 
but 59% of febrile children in high prevalence areas had malaria [13]. Models of malaria 71 
transmission predict that, for children under the age of five, clinical incidence of malaria is 72 
strongly increasing with prevalence [14,15] 73 
In this study we investigate whether ACT treatment patterns for febrile illnesses 74 
correspond to patterns of malaria infection by patient age and by local prevalence. We focus on 75 
age and prevalence as these are two factors that have been shown to be strongly correlated with 76 
the probability of malaria infection in febrile patients. We hypothesized that patterns of ACT 77 
treatment are related to household beliefs about the likelihood of a febrile illness being malaria. 78 
In order to test this, we also examine how malaria beliefs vary with the age of the febrile 79 
individual and with local prevalence. In addition, we directly examine the association between 80 
malaria beliefs and ACT treatment and compare this to the association between other household, 81 
respondent, and febrile individual characteristics hypothesized to be important for ACT 82 
treatment. We use data from a unique household survey in Eastern Uganda that asked about 83 
household malaria treatment behavior and malaria beliefs, and also included a malaria rapid 84 
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diagnostic test of all household members. This study provides evidence on the extent to which 85 
household beliefs about malaria may contribute to the under-treatment of malaria.  86 
 87 
Methods 88 
Ethics Statement 89 
Ethical approval for this study was granted by the Harvard School of Public Health 90 
Internal Review Board (Protocol# P19371-105) and the Uganda National Council for Science 91 
and Technology (Protocol # HS805). Written consent was obtained from all interviewed 92 
respondents.  93 
 94 
Study Context and Population 95 
This study used data from a household survey that was conducted over 9 weeks between 96 
March and May 2012 in 92 villages in six districts in Eastern Uganda: Budaka, Bukedea, 97 
Kibuku, Kumi, Ngora and Pallisa. Malaria is highly endemic in this region with over 100 98 
infective bites per person per year and peaks in transmission during the rainy seasons which 99 
occur in the months of March through May and September to December [16].   100 
The household survey was conducted as part of a randomized controlled trial that tested 101 
the feasibility and impact of introducing rapid diagnostic tests for malaria in private sector drug 102 
shops, described in more detail in previously published work [9,17].  2,285 households were 103 
visited for a baseline survey in March and April 2011 and were visited again for monthly follow-104 
up surveys for nine months to ask about illnesses household members experienced in the month 105 
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prior to the survey. This analysis used only the last survey round, when all consenting adults and 106 
all children whose parents or caregivers gave consent for them, were tested for malaria using a 107 
rapid diagnostic test (RDT). The RDT used in this study was the CareStart Malaria HRP2 (Pf) 108 
test (Access Bio, Somerset, USA). This test has a panel detection score of 98.7%, a false-109 
negative rate of < 1% and a total false-positive rate of 2.4% [18].  110 
 111 
Data 112 
The survey asked the female household head (i.e. the female primarily responsible for 113 
household health decisions) to list illnesses that any member of the household had in the month 114 
prior to the survey, including the start and end date. For children under the age of 18, in 75% of 115 
cases the respondent was the mother of the patient and in 13% of cases she was the grandparent 116 
(in the remaining cases, the respondent was another relative, like an aunt). The respondent was 117 
questioned about the symptoms experienced, and was also specifically asked if the sick 118 
individual had any of a number of symptoms including fever, chills, headache, joint pain, loss of 119 
appetite, diarrhea, vomiting, stomach pains and runny nose/congestion. The respondent was then 120 
asked about the sequence of treatments sought for the illness, what drugs were obtained, whether 121 
the sick individual was tested for malaria, and the result of the test. Respondent perceptions of 122 
the likelihood that the illness was malaria were elicited using a visual analog ladder scale.  123 
We supplemented this data on illness treatment with household demographic information, 124 
and with data from a census of all local public health facilities and licensed drug shops, also 125 
conducted as part of the main study, which included the GPS co-ordinates of the facilities and 126 
information about ACT stocks.  127 
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Analytical Approach 128 
We investigated whether ACT treatment for febrile illnesses, and beliefs about whether a 129 
febrile illness was malaria, corresponded to patterns of malaria infection (as measured by the 130 
RDT) by the age of the febrile individual and by the village prevalence rate. We focused on 131 
febrile illnesses, as fever is the symptom most strongly associated with malaria and is also used 132 
as a WHO indicator of suspected malaria in malaria-endemic areas [1,2]. Since no formal 133 
definition of fever was given to the respondent, our analysis relied on febrile illnesses as self-134 
reported by the respondent. Importantly, since the RDT was performed at the end of the survey, 135 
respondents did not know the RDT result of household members when responding to questions 136 
about ACT use and malaria likelihood.  137 
The RDT identifies a malaria infection by detecting the presence of an antigen known as 138 
histidine-rich protein 2 (HRP) which can persist several weeks after the malaria infection has 139 
cleared [19].  Studies have found that 88-98% of individuals still have a positive RDT test result 140 
14 days after beginning treatment [20–22].  The RDT, therefore, is not only a measure of a 141 
current infection, but can also detect one that may have been treated and cured up to two weeks 142 
before the test. Our sample, therefore, consisted of all febrile episodes that ended no more than 143 
14 days prior to the date of the survey (which was also the date of the RDT). This methodology 144 
for measuring malaria infection and treatment rates is also used by the World Health 145 
Organization in the two most recent “World Malaria Reports” [1,23].  146 
Our first outcome of interest was whether a febrile individual had clinical malaria. We 147 
defined a febrile illness as malaria if it ended no more than two weeks before the survey and the 148 
patient tested positive for malaria on the survey RDT.  149 
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Our second outcome of interest was whether the febrile individual was reported to have 150 
been treated with an ACT at any time during the illness episode. For each illness, the respondent 151 
was asked what drugs were used at home, and what drugs were given or purchased at a health 152 
facility or drug shop. A drug was coded as an ACT either if the respondent said it was an ACT, 153 
or gave the name or brand of a particular type of ACT (such as “Coartem” or “Lumartem”). We 154 
excluded from the analysis the 7 individuals who reported previously testing negative for 155 
malaria, but tested positive for malaria when we performed the RDT at the end of the survey. 156 
These individuals may have become infected between the time they sought treatment for their 157 
illness and the survey and their fever may have been due to another cause.  158 
Our final outcome of interest was whether the respondent believed that the febrile 159 
individual’s illness was malaria. One measure of the respondent’s beliefs about whether the 160 
illness was malaria was if she mentioned “malaria” when asked what the febrile individual’s 161 
health problem was. However, some respondents simply gave symptoms in response to this 162 
question. For all febrile illnesses, respondents were also asked what they thought was the 163 
likelihood that the illness was malaria on a visual analog ladder scale from 0 (no chance of 164 
malaria) to 10 (definitely malaria). Therefore, we defined a respondent as believing an illness 165 
was malaria if she either reported the health problem as “malaria”, or if she gave a rating 166 
between 8 and 10 on the 0-10 scale. While the proportion of febrile illnesses perceived to be 167 
malaria was sensitive to the way this variable is defined, the patterns of beliefs by age of the 168 
individual, and by village prevalence, were generally similar regardless of how we defined a 169 
respondent’s beliefs about whether a febrile illness was malaria (S1 Fig).  In all analyses that 170 
include respondents’ beliefs about whether the illness was malaria, we excluded the 165 febrile 171 
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individuals who had already received a malaria test, as the respondents’ beliefs may have been 172 
influenced by the test result.  173 
Our two independent variables were the age of the febrile individual and the village 174 
malaria prevalence rate. Prevalence was defined as the proportion of 2-10 year olds in the village 175 
who tested positive for malaria on the RDT (regardless of whether they reported any symptoms). 176 
We used the proportion of 2-10 year olds testing positive, instead of the proportion of all ages 177 
testing positive, as this is considered a stable measure of local prevalence [24]. We excluded the 178 
febrile individual’s own RDT status when calculating the village prevalence rate for each 179 
individual. Furthermore, when investigating the relationship between village prevalence and the 180 
outcomes of interest, we limited the sample to children under the age of five. For older ages, the 181 
relationship between malaria prevalence and clinical incidence is not straightforward because in 182 
high-prevalence areas, adults are likely to have higher natural immunity to the disease resulting 183 
from greater exposure to the parasite when young [15,25].  184 
We provide graphical evidence to show how each of the outcomes vary with the age, and 185 
with the village malaria prevalence rate, of individuals who had a fever in the two weeks prior to 186 
the survey. We binned febrile individuals ages into 1-year age groups for individuals under the 187 
age of 5, and 5-year age groups for individuals aged 5 and above. For village prevalence rates—188 
which ranged from 0.08 to 0.93— we divided them into 0.10 unit bins. The mean of the outcome 189 
(malaria positivity rates, ACT treatment rates, malaria beliefs) was calculated within each bin 190 
and plotted against febrile individual age and, separately, against village prevalence rates. On the 191 
same graphs, we also included a local polynomial or local linear regression line, and 95% 192 
confidence intervals, of the outcome on the independent variable of interest (for the regression 193 
line we do not bin age/village prevalence).  194 
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We used logistic regressions to test whether the graphical relationships were statistically 195 
significant and to control for other factors that might influence ACT use and also be associated 196 
with our variables of interest. The control variables, which have been shown to either influence 197 
treatment-seeking for febrile illnesses, or to be directly associated with the use of ACTs, 198 
included the education level of the respondent, whether he/she could read a basic letter in 199 
English, the wealth quintile of the household, the distance of the household to the closest health 200 
center, hospital, clinic, and drug shop, and whether ACTs were available at the closest licensed 201 
drug shop at the time of the survey [4,26–31].  We tested the equality of coefficients from 202 
separate models with either malaria positivity as an outcome or ACT treatment as an outcome 203 
using the “suest” command in STATA which estimates both models simultaneously.  204 
In addition, we show both the bi-variate and multi-variate associations between ACT 205 
treatment—for both febrile illnesses and RDT-positive febrile illnesses— and respondents’ 206 
beliefs about whether the illness was malaria, the age of febrile individual, village prevalence 207 
and the control variables. For the multi-variate model, we also performed stepwise backward-208 
selection estimation of a logistic model (using the “stepwise” command in STATA). The 209 
significance level for removal from the model was 0.2. 210 
We defined a respondent as having some primary education if they completed part of, or 211 
all of, primary school (but had no further education). A respondent was defined as having some 212 
secondary education if they had any education beyond primary school. We assigned households 213 
to wealth quintiles using a principal component analysis of housing characteristics and household 214 
ownership of durable assets and farm animals [32]. Distance to the nearest health facility and 215 
drug shop was based on the GPS co-ordinates of the households and the health facilities, and was 216 
calculated using the length of the shortest curve between the two GPS co-ordinates along the 217 
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surface of a mathematical model of the earth. A drug shop was defined as stocking ACTs if the 218 
drug shop attendant mentioned it as one of the five most frequently sold anti-malarial drugs. This 219 
variable was missing for 156 people in the sample. For 93 of these people, the missing value was 220 
imputed as the mean proportion of drug shops in the person’s village that had ACTs available. 221 
All regressions with ACT stocks also include an indicator variable to indicate which of these 222 
observations had missing values that were imputed.   223 
In all regressions, standard errors were adjusted for clustering at the village level (using 224 
the STATA cluster command) as this was the level at which households were randomly sampled. 225 
All analyses were conducted using Stata/SE version 11 (StataCorp, College Station, TX) [33].  226 
 227 
Results 228 
Sample Characteristics and Malaria Positivity Rates 229 
The survey was conducted with respondents from 2,285 households and included 9,887 230 
individuals as members of those households. Table 1 presents some summary statistics on the 231 
1,342 individuals who had a fever in the two weeks prior to the survey and on the respondents 232 
for these individuals. 20% of respondents had no education, while 62% had some primary 233 
education. Only 31% could read a simple letter in English. Febrile individuals were from 234 
households that were relatively poor: while 83% owned some land, only 5% had electricity, and 235 
57% owned at least one mobile phone.  236 
 237 
 238 
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Table 1. Summary Statistics of Respondent, Household, and Febrile Individual 239 
Characteristics and Treatment-Seeking Behavior. 240 
  
% or Mean 
±SD Observations 
A. Characteristics of Respondent   
Age 35.0 ± 12.4 1288 
Female 96% 1338 
No Education 20% 1334 
Some Primary Education 62% 1334 
Some Secondary Education 17% 1334 
Can Read English 31% 1342 
B. Characteristics of Household   
Has Electricity 5% 1340 
Owns Mobile Phone 57% 1342 
Owns Land 83% 1342 
Number of Household Members 7.33 ± 3.40 1342 
Village Malaria Prevalence Rate in 2-10 year olds 63% 1342 
Village Malaria Prevalence Rate among all ages 48% 1342 
C. Household Distance to Health Facilities   
Distance to closest Health Center (km) 2.01 ± 1.81 1341 
Distance to closest Hospital (km) 10.2 ± 5.67 1341 
Distance to closest private clinic (km) 3.50 ±  3.34 1341 
Distance to closest drug shop (km) 0.79 ± 0.91 1341 
Distance to closest licensed drug shop (km) 1.61 ± 1.70 1341 
ACTs available at closest licensed drug shop 82% 1279 
D. Characteristics of Febrile Individual   
Age 13.9 ±  18.0 1312 
Under 5 44% 1342 
Female 58% 1342 
Tested Positive for Malaria 52% 1342 
E. Treatment-Seeking for Febrile Illness   
Ever Sought Care 58% 1342 
Sought Care in Public Sector 20% 1342 
Sought Care at Private Clinic 7% 1342 
Sought Care at Drug Shop 33% 1342 
F. Malaria Testing and Treatment   
Ever Tested at Health Facility/Drug Shop 12% 1335 
Tested Positive for Malaria (Among Those Tested) 76% 172 
Took ACT anywhere 42% 1342 
Took ACT if Treated at Home 36% 559 
Took ACT if Treated Outside Home 46% 783 
14 
 
Took ACT if Tested Positive at Health Facility/Drug 
Shop 54% 131 
Took Other Anti-Malarial Drug 21% 1342 
Respondent Reported Illness Was Malaria 34% 1342 
Sample is limited to individuals who had a fever in the two weeks prior to the survey.  241 
 242 
 243 
The mean village malaria prevalence rate was 63% in children aged 2-10 years. The 244 
distance to the closest health center was, on average, 2 km, while the mean distance to the closest 245 
drug shop (either licensed or unlicensed) was less than half of that at 0·8km. 82% of households 246 
had ACTs available at their closest licensed drug shop which was, on average, 1.6km away.  247 
584 of the 1,342 (44%) febrile episodes were among children under the age of five.  248 
Among the 1,342 febrile episodes, 702 (52%) tested positive for malaria when they were tested 249 
at the end of the survey, and 343 children under the age of five (59%) tested positive for malaria 250 
at the end of the survey. 58% of febrile individuals received care from outside the home for their 251 
febrile illness, 33% went to a drug shop, while 20% were treated in the public sector.  252 
Only 12% of febrile individuals had received a diagnostic test for malaria at either a 253 
health facility or drug shop. Of those tested, 76% reported a positive test, and 54% of those who 254 
said they tested positive reported taking an ACT.  36% of febrile individuals who did not seek 255 
care outside the home reported taking an ACT, while 46% of people who sought care outside the 256 
home said they took an ACT. Among all febrile individuals, 21% reported taking a non-ACT 257 
antimalarial. Respondents reported 34% of the febrile illnesses as malaria.  258 
Malaria Positivity and ACT use by Age of Febrile individual and by 259 
Village Prevalence 260 
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Fig 1 shows how malaria infection rates and ACT use varied with the age of febrile 261 
individuals. The malaria positivity rate in febrile individuals declined substantially with age, 262 
from 60% to 30% between the ages of 0-45 (Fig 1A). Compared to febrile individuals who were 263 
aged 15 or above, febrile children aged 5-14 had 3.21 times the odds of testing positive for 264 
malaria (95% CI: [2.36 4.37], P<0·001), and febrile children who were under 5 had 2.66 times 265 
the odds of testing positive for malaria (95% CI: [1.99 3.56], P<0·001) with very similar effects 266 
when adjusted for covariates (S1 Table). However, febrile children were not comparatively more 267 
likely to be treated with an ACT than febrile individuals aged 15 or above (Fig 1B). Compared to 268 
those aged 15 or above, the odds of being treated with an ACT were not significantly higher for 269 
children under the age of 5 (Unadjusted OR: 1.24, 95% CI: [0.92 1.68], P=0·154; Adjusted OR: 270 
1.20, 95% CI [0.87 1.64], P=0·269) or children ages 5-14 (Un-adjusted OR: 1.19, 95% CI: [0.88 271 
1.62], P=0.255, Adjusted OR: 1.29, 95% CI: [0.94 1.77], P=0.112) (S1 Table). 272 
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 273 
Fig 1. Malaria Infection Rates and ACT Use by Age. (A) The proportion of febrile individuals 274 
who tested positive for malaria on the RDT. (B) The proportion of febrile individuals who were 275 
treated with an ACT. Figure shows mean of the outcome within 1 year (for ages under 5) or 5-276 
year (for ages 5 and above) age groups. A local polynomial regression line is also plotted and the 277 
grey shaded areas indicate 95% confidence intervals. Data is limited to individuals who had a 278 
fever in the two weeks prior to the survey. Ages above 60 are excluded because of small sample 279 
size. 280 
 281 
Our sample consisted of febrile individuals living in villages with malaria prevalence 282 
rates in 2-10 year olds ranging from 8% to 93% (S2 Fig). The malaria positivity rate in febrile 283 
individuals under the age of five increased from 0% in the lowest prevalence villages to 84% in 284 
the highest prevalence villages (Fig 2). A one standard deviation increase in the village 285 
prevalence rate was associated with 2.03 times higher odds that a febrile child under the age of 286 
five tested positive for malaria (95% CI: [1.63 2.54], p<0·001; Adjusted OR: 1.68, 95% CI: [1.31 287 
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2.16], p<0·001) (S2 Table).  However, the likelihood that a febrile child was treated with an 288 
ACT does not increase with village prevalence (Fig 2). A one standard deviation increase in the 289 
village prevalence rate was associated with lower odds that a febrile episode in a child under 5 290 
was treated with an ACT (Unadjusted OR: 0.83, 95% CI: [0.66 1.05], P=0·113; Adjusted OR: 291 
0.75, 95% CI: [0.60 0.93], P=0·010) (S2 Table).  292 
 293 
Fig 2. Malaria Infection Rates and ACT Use by Village Prevalence. (A) The proportion of 294 
febrile individuals who tested positive for malaria on the RDT. (B) The proportion of febrile 295 
individuals who were treated with an ACT. Figure shows mean of the outcome within 0.10 units 296 
of village prevalence. A local linear regression line is also plotted and the grey shaded areas 297 
indicate 95% confidence intervals. Data is limited to individuals who had a fever in the two 298 
weeks prior to the survey and to individuals under the age of five.  299 
 300 
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The odds that a clinical malaria episode (a fever with a positive RDT) was treated with an 301 
ACT was also not significantly associated with the age of the febrile individual age and was 302 
lower with increasing village malaria prevalence rates (S3 Fig, S1 Table, S2 Table). 303 
 304 
Malaria Beliefs 305 
We now turn from treatment of febrile illnesses to beliefs about whether the illness was 306 
malaria. Respondents reported 34% of febrile illnesses across all ages as malaria, with a slightly 307 
higher percent among febrile individuals aged 20-30 (Fig 3). Compared with febrile individuals 308 
ages 15 and above, respondents did not have higher odds of reporting that the illness was malaria 309 
for children ages 5-14 (Unadjusted OR: 1.04, 95%CI:[ 0.71 1.53], P=0·829; Adjusted OR: 1.17, 310 
95% CI:[ 0.80 1.70], P=0·421)   or children under the age of 5 (Unadjusted OR: 0·94, 95% CI: 311 
[0.72 1.24], P=0·677; Adjusted OR: 0.97, 95% CI:[ 0.71 1.33], P=0·863)  (S3 Table). Similarly, 312 
Fig 3 suggests that beliefs about whether a febrile illness in a child under 5 was malaria were not 313 
associated with malaria prevalence. A one standard deviation increase in the village malaria 314 
prevalence rate was associated with 0.87 times the odds that a respondent identified a febrile 315 
illness in a child under 5 as malaria (95% CI: [0.70 1.08], P=0·213, Adjusted OR: 0.89, 95% CI: 316 
[0.70 1.14], P=0.365) (S3 Table).  317 
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 318 
Fig 3. Malaria Beliefs by Age and Prevalence. (A) The proportion of febrile illnesses reported 319 
as malaria by the age of the febrile individual. (B) The proportion of febrile illnesses reported as 320 
malaria by the village prevalence rate. Figure shows mean of the outcome within 1-year age 321 
groups (for children under 5) or 5-year age groups (for ages 5 and above) and 0.10 units of 322 
village prevalence. A local linear regression line is also plotted and the grey shaded areas 323 
indicate 95% confidence intervals. Sample is limited to individuals who had a fever in the two 324 
weeks prior to the survey and who were not previously tested for malaria. Ages above 60 are 325 
excluded because of small sample size. In Figure 3B, sample is limited to children under the age 326 
of 5.  327 
 328 
 329 
Factors Associated with ACT treatment for Febrile Illnesses 330 
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Table 2 compares the magnitude of the bi-variate and multi-variate associations between 331 
respondent, febrile individual, and household characteristics and use of ACTs to treat a febrile 332 
illness (Columns 1 and 2) and ACT treatment of RDT-positive febrile episodes (Columns 3 and 333 
4). A febrile individual who was believed by the respondent to have malaria had 2.54 times the 334 
odds of being treated with an ACT (95% CI: [1.86 3.47], P<0·001, Adjusted OR: 2.43, 95% CI: 335 
[1.78 3.33], P<0.001), which suggests that people’s perceptions of whether an illness is malaria 336 
are important in influencing the probability that a febrile individual is treated with an ACT. 337 
Similarly, a clinical malaria episode (an individual who had a fever and tested positive for 338 
malaria on the survey RDT) had 2.73 times higher odds of being treated with an ACT if the 339 
respondent believed the illness was malaria (95% CI: [1.83 4.07], P<0.001, Adjusted OR: 2.68, 340 
95% CI: [1.79 4.01], P<0·001). 341 
 342 
Table 2: Factors Associated with ACT use for Febrile Episodes and Clinical Malaria 343 
Episodes 344 
 
Febrile Episode Treated with ACT  
RDT-Positive Febrile Episode 
Treated with ACT 
 OR aOR   OR aOR 
Respondent Believed 
Illness Was Malaria 
            2.54**             2.43**              2.73**             2.68** 
     [1.86,3.47]        [1.78,3.33]         [1.83,4.07]        [1.79,4.01]   
                                          
Individual is Aged 15 and 
above 
Ref. Group Ref. Group 
 
Ref. Group Ref. Group  
 
     
Child Aged 5-14 
1.24 1.32  1.23 1.49 
     [0.89,1.71]        [0.94,1.86]         [0.79,1.91]        [0.93,2.40]   
      
Child Under Age 5 
1.21 1.18  1.39 1.43 
     [0.87,1.68]        [0.84,1.64]         [0.88,2.19]        [0.91,2.26]   
      
0.87             0.85*   0.84             0.73*  
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Standardized Village 
Prevalence Rate      [0.72,1.06]        [0.73,0.99]         [0.62,1.14]        [0.55,0.97]   
 
     
Respondent Has No 
Education 
Ref. Group Ref. Group  Ref. Group Ref. Group 
 
      
Respondent Has Some 
Primary Education 
            2.31**             2.15**              1.98*              1.80*  
     [1.51,3.55]        [1.38,3.36]         [1.15,3.41]        [1.06,3.07]   
      
Respondent Has Some 
Secondary Education 
            3.02** 1.92              2.12*  1.44 
     [1.67,5.47]        [0.93,3.96]         [1.02,4.40]        [0.65,3.20]   
      
Respondent Can Read 
English 
            1.64** 1.18  1.37 1.29 
     [1.21,2.21]        [0.77,1.81]         [0.93,2.01]        [0.79,2.10]   
 
     
Household In First 
Wealth Quintile (Poorest) 
Ref. Group Ref. Group  Ref. Group 
Ref. Group 
 
 
      
Household In Second 
Wealth Quintile 
1.22 1.06  1.35 1.08 
     [0.79,1.88]        [0.67,1.65]         [0.79,2.31]        [0.64,1.85]   
      
Household In Third 
Wealth Quintile 
0.98 0.92  1.1 1.01 
     [0.66,1.48]        [0.61,1.38]         [0.69,1.75]        [0.62,1.65]   
      
Household In Fourth 
Wealth Quintile 
1.61 1.5  1.09 1.13 
     [0.95,2.71]        [0.90,2.51]         [0.55,2.14]        [0.60,2.11]   
      
Household In Fifth 
Wealth Quintile (Richest) 
            1.84*  1.33  1.26 0.79 
     [1.05,3.24]        [0.73,2.42]         [0.56,2.83]        [0.33,1.89]   
 
     
Household distance to 
closest health center 
(km)  
1 1.04  1 1.03 
     [0.90,1.12]        [0.96,1.12]         [0.87,1.15]        [0.93,1.15]   
      
Household distance to 
closest hospital (km)       
0.99 1  0.98 0.98 
     [0.96,1.01]        [0.98,1.02]         [0.94,1.02]        [0.95,1.01]   
      
Household distance to 
closest clinic (km)       
0.97 0.98  0.99 0.98 
     [0.92,1.02]        [0.93,1.03]         [0.92,1.06]        [0.92,1.04]   
      
Household distance to 
closest drug shop(km)       
            1.16*              1.16*               1.25**             1.23** 
     [1.04,1.31]        [1.03,1.30]         [1.08,1.44]        [1.08,1.40]   
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ACTs available at closest 
licensed drug shop 
1.36             1.47*   1.56             1.76*  
     [0.89,2.08]        [1.07,2.00]         [0.83,2.92]        [1.08,2.86]   
      
Proportion Treated with 
an ACT 0.4 0.4  0.39 0.39 
Number of Obs 1103 1103   597 597 
 345 
Notes: Columns 1 and 2 show associations with the odds of ACT treatment for a febrile illness, 346 
while Columns 3 and 4 present associations with the odds of ACT treatment for an RDT-positive 347 
febrile illness. Columns 1 and 3 are bi-variate regressions and columns 2 and 4 are multi-variate 348 
regressions. Confidence intervals are in brackets and adjusted for clustering at the village level. 349 
*p<0.05, **p<0.01 350 
 351 
In the multi-variate regression (Column 2), odds of ACT treatment for a febrile episode 352 
was higher if the respondent had some primary education (Adjusted OR:2.15, 95% CI: [1.38 353 
3.36], P=0.001), if ACTs were available at the closest drug shop (Adjusted OR:1.47, 95% CI: 354 
[1.07 2.00], P=0.016) and as distance to the closest drug shop increased (Adjusted OR:1.16, 95% 355 
CI: [1.03 1.30], P=0.012) with similar results for the odds of ACT treatment for RDT-positive 356 
febrile episodes (Column 4). In both the bi-variate and multi-variate regressions, age was not 357 
significantly associated with the odds of ACT treatment for both febrile episodes and clinical 358 
malaria episodes and in the multi-variate models, increasing village malaria prevalence was 359 
associated with statistically significant lower odds of ACT treatment. Results from using a 360 
stepwise approach to estimate the model are very similar (S4 Table).  361 
 362 
Discussion 363 
Nearly 80% of children with malaria worldwide do not receive ACTs [1]. Using a 364 
household survey from Uganda, and the WHO methodology for appropriate treatment of malaria, 365 
we found that, although the age of the febrile individual and the village prevalence rate were 366 
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strongly associated with malaria infection among febrile individuals, ACT treatment rates were 367 
not correspondingly higher among young children or in high-prevalence villages. Moreover, 368 
people’s beliefs about whether a febrile illness was malaria did not vary with the age of the 369 
febrile individual or with village prevalence, which suggests that household misperceptions 370 
about malaria risk may play an important role in the under-treatment of malaria. 371 
We show that respondents’ beliefs about malaria are strongly associated with the odds 372 
that a febrile individual was treated with an ACT, even when controlling for other factors that 373 
might influence ACT treatment and be associated with beliefs about malaria likelihood. We also 374 
find associations between ACT treatment and whether the respondent had a primary education, 375 
whether ACTs were available at the closest drugs shop, and with distance to the closest drug 376 
shop. These results are consistent with previous studies indicating the importance of education 377 
and access to drugs in malaria treatment [26,31,34]. The positive association between distance to 378 
a drug shop and ACT treatment is, however, unexpected. While we do not have any evidence on 379 
why this is the case, one possible explanation is that households further from a drug shop may be 380 
more likely to visit a health facility and, therefore, have a higher likelihood of receiving ACT 381 
treatment. 382 
It is possible that the inverse relationship we observe between the proportion of children 383 
treated with an ACT and village prevalence results from variations in ACT coverage across 384 
different villages. For example, villages with the highest ACT coverage rates could be expected 385 
to have the lowest prevalence of malaria due to potential effects of ACT treatment on reducing 386 
malaria transmission (particularly in low-transmission settings) [35–38]. However, we did not 387 
find substantial variations across villages in the availability of ACTs at either public health 388 
facilities or at licensed drug shops– in villages across all prevalence levels, more than 90% of 389 
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public health facilities had ACTs available at the time of the survey, while approximately 80% of 390 
licensed drug shops had ACTs available (S4 Fig). This suggests that the patterns of ACT 391 
treatment by village prevalence are not simply a result of variations in ACT access.  392 
We also found that among those who received diagnostic testing for malaria, and tested 393 
positive, only 54% of sick individuals took an ACT (a much higher proportion- 91% took any 394 
type of anti-malarial drug). This indicates that additional efforts are needed to increase the 395 
availability and affordability of ACTs. Our results on malaria beliefs also suggest, however, that 396 
households may not seek malaria testing and treatment for fevers that they do not suspect to be 397 
malaria. This underscores the urgency of public health messaging that emphasizes the 398 
importance of all fevers being tested for malaria and receiving appropriate treatment for the 399 
illness. Furthermore, the messaging could focus on the importance of febrile individuals getting 400 
tested even when the caregiver believes the illness is unlikely to be malaria, because of the 401 
difficulty of identifying the disease on the basis of symptoms alone. In order for this policy to be 402 
successful, there will also need to be improved access to diagnostic testing, as well as 403 
interventions to raise confidence in malaria diagnostic testing which has varied across different 404 
contexts [7–9,39,40] .  405 
 It is particularly concerning that children are under-treated with ACTs. Not only are 406 
children more likely than adults to have malaria, but the disease is more likely to develop into a 407 
severe and life-threatening illness in children [41]. Several studies have found no differences in 408 
treatment-seeking patterns, or in the probability of being treated with an ACT, by the age of the 409 
sick individual [27,30,31,42]. Our results suggest that this may be related to caregivers’ mis-410 
perceptions about the relative likelihood of malaria in febrile children compared to febrile adults.   411 
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This study has some limitations. First, people who have developed immunity to the 412 
disease can harbor malaria parasites asymptomatically [43] and may test positive on the RDT 413 
even if their fever is caused by another illness. Since we do not have data on parasite densities or 414 
co-infection, we cannot identify the proportion of fevers that are attributable to malaria using 415 
logistic regression methods [44,45].  However, according to WHO guidelines, all individuals 416 
with a fever who test positive for malaria should be treated with ACTs and therefore this is the 417 
definition that we use to identify illnesses that should have received ACT treatment [2]. 418 
Furthermore, immunity to malaria disease generally develops with age, particularly in areas of 419 
high malaria transmission [25,43]. When comparing across villages with different malaria 420 
prevalences, we limit our analysis to children under the age of five for whom there is a consistent 421 
relationship between increasing prevalence and higher incidence of clinical malaria episodes 422 
[15].  423 
Second, the malaria RDT we used in this study only detects infections caused by 424 
Plasmodium falciparum and, therefore, we may have missed infections that were caused by non-425 
falciparum species [46]. However in Uganda, P. falciparum is responsible for between 90-97% 426 
of malaria cases [47].  427 
Third, we relied on respondents’ self-reports of whether an individual had a fever in the 428 
two weeks prior to the survey and of whether the individual took an ACT. This may be affected 429 
by recall bias, social desirability bias and respondent knowledge of ACTs. By relying on 430 
respondents’ self-reports of whether the individual had a fever, we may have either under-431 
estimated or over-estimate cases of clinical malaria.  432 
Fourth, the respondent was asked about their beliefs about whether an illness was malaria 433 
in retrospect rather than prior to beginning treatment. It is possible that the treatment that was 434 
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chosen for the illness, and the outcome of the illness, influenced their perceptions of whether the 435 
illness was malaria.  436 
Finally, the generalizability of these results is limited by the fact that the survey occurred 437 
over a few months (March-May) in one part of Eastern Uganda. As households were surveyed 438 
over 9 weeks (the rainy season) it is unlikely that differences in measured prevalence rates are 439 
due to variations in season. However, the patterns of beliefs and behavior that we found in this 440 
study may vary by season or by location, and by the availability of ACTs relative to other anti-441 
malarial drugs. Moreover, since this entire region is highly endemic for malaria, our results may 442 
not be relevant to low transmission and pre-elimination settings.  443 
The likelihood that an  individual with malaria is treated with an ACT depends on 444 
whether they (or their caregivers) decide to seek care, the availability and cost of ACTs locally, 445 
and their beliefs about the efficacy of those drugs [4,26,28,48].  Our results suggest that 446 
additional policies are needed to encourage caregivers to seek immediate diagnostic testing and 447 
treatment for febrile illnesses to ensure that those at highest risk of malaria receive appropriate 448 
care.  449 
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Supporting Information 612 
S1 Dataset. Household and Illness Survey. Household data from baseline survey and illness 613 
data from final survey round including malaria rapid diagnostic test result. Sample is limited to 614 
those who had a fever in the two weeks prior to the survey.  615 
 616 
 617 
 618 
32 
 
S1 Fig. Robustness of Malaria Beliefs by Age and Prevalence. The figures in the left column 619 
show the proportion of respondents who reported that the illness was malaria. The figures on the 620 
right show the mean of the respondents’ perceived likelihood that the illness was malaria on a 621 
scale of 0-10 (divided by 10 so as to use a similar scale). Points show mean of the outcome 622 
within 5-year age groups or 0.1 units of village prevalence. A local linear regression line is also 623 
plotted and the grey shaded areas indicate 95% confidence intervals. Sample is limited to 624 
patients who were not previously tested for malaria.  625 
 626 
 627 
S2 Fig. Distribution of Village Malaria Prevalence Rates. Positivity Rates are based on the 628 
RDT performed at the end of the survey on children whose parents/caregivers gave consent to 629 
their being tested. Sample is limited to children between the ages of 2 and 10.  630 
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 631 
S3 Fig. ACT Use for Clinical Malaria Episodes by Age and by Village Prevalence. (A) The 632 
proportion of clinical malaria episodes (febrile patients who tested positive on the RDT) treated 633 
with ACTs by the age of the patient. (B) The proportion of clinical malaria episodes treated with 634 
ACTs by the village prevalence rate. Figure shows mean of the outcome within 1-year age 635 
groups (for ages under 5) or 5-year age groups (for ages 5 and above) and 0.10 units of village 636 
prevalence. A local linear regression line is also plotted and the grey shaded areas indicate 95% 637 
confidence intervals. Data is limited to patients who had a fever in the two weeks prior to the 638 
survey and to patients under age 5 (in B). Ages above 60 are excluded because of small sample 639 
size (in A).  640 
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 641 
S4 Fig. ACT Availability in Health Facilities and Drugs Shops by Village Prevalence. The 642 
proportion of health facilities (blue) and drug shops (red) by village prevalence that had ACTs 643 
available at the time of the survey. Health facilities include public clinics, health centers or 644 
hospitals. Points indicate mean proportion for each village and a separate local polynomial 645 
regression line is also included for health facilities and drug shops.  646 
 647 
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 648 
S1 Table. Effect of age on Malaria Positivity and ACT Use.  Table shows un-adjusted and 649 
adjusted logistic regression results of the association between age and the odds that a febrile 650 
individual tested positive for malaria, the odds that a febrile individual was treated with an ACT, 651 
and the odds that an RDT-positive febrile episode was treated with an ACT. The control 652 
variables for the adjusted regressions are as follows: respondent’s education level, whether the 653 
respondent can read English, household wealth quintile, distance to closest clinic, health center, 654 
hospital and drug shop, and whether the closest licensed drug shop stocked ACTs. Equality of 655 
coefficients were tested using the “suest” command in STATA. 95% confidence intervals are in 656 
brackets and adjusted for clustering at the village level. *p<0.05, **p<0.01. 657 
Coefficient on: OR aOR OR aOR OR aOR
            2.66**             2.65** 1.24 1.2 1.47 1.47
     [1.99,3.56]      [1.95,3.61]       [0.92,1.68]      [0.87,1.64]       [0.98,2.21]     [0.96,2.25]  
            3.21**             3.34** 1.19 1.29 1.11 1.4
     [2.36,4.37]      [2.40,4.66]       [0.88,1.62]      [0.94,1.77]       [0.74,1.64]     [0.91,2.14]  
P-value: Coefficient on 
Under 5 for ACT 
Treatment= Coefficient 
on Under 5 for Positivity
Ref Group Ref Group 0.00 0.00 0.02 0.04
P-value: Coefficient on 
Ages 5-14 for ACT 
Treatment = Coefficient 
on Ages 5-14 for Positivity
Ref Group Ref Group 0.00 0.00 0.00 0.00
Proportion Tested 
Positive/Treated with 
ACT
0.52 0.52 0.42 0.42 0.4 0.39
Number of Observations 1335 1256 1335 1256 695 650
Odds Febrile Episode 
Tested Positive for 
Malaria
Odds Febrile Episode 
Treated with ACT
Odds RDT-Positive 
Febrile Episode Treated 
with ACT
Patient Under 5
Patient Aged 15 or Above Ref. Group Ref. Group Ref. Group Ref. Group Ref. Group Ref. Group
Patient Aged 5-14
36 
 
 658 
S2 Table. Effect of Village Prevalence on Malaria Positivity and ACT Use among Children 659 
Under Age 5.  Table shows un-adjusted and adjusted logistic regression results of the 660 
association between the standardized village prevalence rate and the odds that a child under 5 661 
tested positive for malaria, the odds that a child under 5 was treated with an ACT, and the odds 662 
that a clinical malaria episode (fever and RDT positive) in a child under 5 was treated with an 663 
ACT. Individual is excluded from calculation of village prevalence rate. The control variables 664 
for the adjusted regressions are as follows: respondent’s education level, whether the respondent 665 
can read English, household wealth quintile, distance to closest clinic, health center, hospital and 666 
drug shop, and whether the closest licensed drug shop stocked ACTs. Equality of coefficients 667 
were tested using the “suest” command in STATA. 95% confidence intervals are in brackets and 668 
adjusted for clustering at the village level. *p<0.05, **p<0.01. 669 
Coefficient on: OR aOR OR aOR OR aOR
            2.03**             1.68** 0.83             0.75* 0.7             0.58**
     [1.63,2.54]      [1.31,2.16]       [0.66,1.05]     [0.60,0.93]       [0.46,1.07]       [0.38,0.87]  
P-value: Coefficient 
on Village Prevalence 
for ACT Treatment = 
Coefficient on Village 
Prevalence for 
Positivity
Ref Group Ref Group 0.000 0.000 0.000 0.000
Proportion Tested 
Positive/Treated with 
ACT 0.59 0.58 0.44 0.43 0.44 0.43
Number of 
Observations 581 534 581 534 340 311
Standardized Village 
Prevalence Rate
Odds Febrile Episode 
Tested Positive for 
Malaria
Odds RDT-Positive Febrile 
Episode Treated with ACT
Odds Febrile Episode 
Treated with ACT
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 670 
S3 Table. Malaria Beliefs by Patient Age and by Village Prevalence. Un-adjusted and 671 
adjusted logistic regression results of the association between patient age, or the village 672 
prevalence rate, and the odds that a respondent believed the febrile illness was malaria. Adjusted 673 
logistic regressions include the following control variables: respondent’s education level, 674 
whether the respondent can read English, household wealth quintile, distance to closest clinic, 675 
health center, hospital and drug shop, and whether the closest licensed drug shop stocked ACTs. 676 
Sample is limited to individuals who were not previously tested for malaria. Regressions with 677 
village prevalence are limited to children under the age of 5. Individuals who were previously 678 
tested for malaria are excluded. 95% confidence intervals are in brackets and are adjusted for 679 
clustering at the village level. *p<0.05, **p<0.01. 680 
 681 
 682 
  Stepwise Logistic Regression 
 
Odds Febrile 
Episode Treated 
with ACT 
Odds RDT-Positive 
Febrile Episode 
Treated with ACT 
 (1) (2) 
Respondent Believed Illness Was Malaria 
            2.47**             2.65** 
     [1.82,3.34]        [1.80,3.92]   
                                       
Patient is Aged 15 and above Ref. Group Ref. Group 
 
  
Coefficient on: OR aOR OR aOR
0.94 0.97
     [0.72,1.24]      [0.71,1.33]  
1.04 1.17
     [0.71,1.53]      [0.80,1.70]  
0.87 0.89
     [0.70,1.08]       [0.70,1.14]  
Proportion Believed 
Illness Was Malaria
0.3 0.3 0.29 0.29
Number of 
Observations
1170 1103 508 469
Odds Respondent Believed Illness Was Malaria
Patient Under 5
Patient Aged 5-14
Standardized Village 
Prevalence Rate
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Patient Aged 5-14  
1.45 
      [0.90,2.34]   
   
Patient Under Age 5  
1.42 
      [0.89,2.28]   
   
Standardized Village Prevalence Rate 
0.86             0.74*  
     [0.73,1.01]        [0.55,1.00]   
 
  
Respondent Has No Education Ref. Group Ref. Group 
   
Respondent Has Some Primary Education 
            2.24**             1.90*  
     [1.45,3.44]        [1.11,3.24]   
   
Respondent Has Some Secondary 
Education 
            2.24** 1.78 
     [1.24,4.05]        [0.88,3.60]   
   
Respondent Can Read English  
 
  
 
  
Household In First Wealth Quintile 
(Poorest) 
Ref. Group Ref. Group 
   
Household In Second Wealth Quintile   
  
   
Household In Third Wealth Quintile   
  
   
Household In Fourth Wealth Quintile 
            1.54*   
     [1.01,2.33]    
   
Household In Fifth Wealth Quintile 
(Richest) 
1.39  
     [0.88,2.20]    
 
  
Household distance to closest health 
center (km)  
  
  
   
Household distance to closest hospital 
(km)       
 0.98 
      [0.95,1.01]   
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Household distance to closest clinic (km)         
  
   
Household distance to closest drug 
shop(km)       
            1.15*              1.20** 
     [1.02,1.28]        [1.06,1.37]   
   
ACTs available at closest licensed drug 
shop 
            1.50**             1.74*  
     [1.11,2.04]        [1.10,2.76]   
                                       
Proportion of people who took an ACT 0.4 0.39 
Number of Observations 1103 597 
 683 
S4 Table. Factors Associated with ACT treatment using Stepwise Multivariate Logistic 684 
Regression. Results are from a stepwise backward-selection estimation of a logistic model 685 
(using the “stepwise” command in STATA). The significance level for removal from the model 686 
was 0.2. 95% confidence intervals are in brackets and are adjusted for clustering at the village 687 
level. *p<0.05, **p<0.01 688 
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